# Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors

> **NCT05580991** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Canwell Biotech Limited** · enrollment: 27 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** CAN1012

## Key facts

- **NCT ID:** NCT05580991
- **Lead sponsor:** Canwell Biotech Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-09
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05580991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05580991, "Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05580991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*